Stifel Financial
ENSC icon

Stifel Financial’s Ensysce Biosciences ENSC Stock Holding History

Stifel Financial’s Portfolio ENSC Stock Details ENSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-60
Closed -$8.12K – 3353
2022
Q4 		$8.12K Hold
60
– – ﹤0.01% 3274
2022
Q3 		$47K Hold
60
– – ﹤0.01% 3188
2022
Q2 		$188K Hold
60
– – ﹤0.01% 3023
2022
Q1 		$247K Hold
60
– – ﹤0.01% 2995
2021
Q4 		$1.02M Sell
60
-30
-33% -$283K ﹤0.01% 2118
2021
Q3 		$980K Buy
+90
New +$1.76M ﹤0.01% 2122

Other funds holding ENSC

VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
PIA
Powell Investment Advisors Miami, Florida $317M AUM 26.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $8.83B AUM 38.5% 1-Year Est. Return
PMFA
Plante Moran Financial Advisors Southfield, Michigan $2.15B AUM 22.82% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Stifel Financial's ENSC Position: Q1 2023 in Review

Stifel Financial sold out of Ensysce Biosciences (ENSC) in Q1 2023, closing a stake of 60 shares — an estimated $8.12K sold.

Stifel Financial first reported a position in ENSC in Q3 2021 and held it in 6 quarters. The position peaked at $1.02M in Q4 2021. 8 funds tracked by Wall St. Rank hold ENSC as of Q1 2023.

  • Stifel Financial reported no remaining Ensysce Biosciences position as of Q1 2023 after selling out during the quarter.
  • Stifel Financial sold 60 Ensysce Biosciences shares in Q1 2023, an estimated $8.12K.
  • Stifel Financial first reported a position in Ensysce Biosciences in Q3 2021 and held it in 6 quarters.
  • Stifel Financial's Ensysce Biosciences position peaked at $1.02M in Q4 2021.
  • 8 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q1 2023.

Based on Stifel Financial's 13F filing for Q1 2023, filed 12 May 2023.